QUOTE AND NEWS
SeekingAlpha  Mar 17  Comment 
By Bill Gunderson: Ligand Pharmaceuticals (LGND) A cash-cow biotech 2014 is off to a lot tougher start than 2013. By this time last year, the S&P was already up 9.6%, and it was well on its way to a 29.6% gain before the year was...
DailyFinance  Mar 10  Comment 
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Captisol® licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational...
StreetInsider.com  Feb 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Ligand+Pharma+%28LGND%29%2C+Glaxo+%28GSK%29+Submit+sNDA+for+Promacta+to+FDA/9230662.html for the full story.
SeekingAlpha  Feb 25  Comment 
By Small Pharma Analyst: Executive Summary Although the stock price of Ligand Pharmaceuticals has soared nearly 4-fold over the past year, the anticipated rapid EPS growth over the next 3 years, with limited downside risk, makes this...
SeekingAlpha  Feb 21  Comment 
By Chris Katje: Executive summary: · Ligand Pharmaceuticals has 85 fully funded programs in trials · Recently approved Duavive could provide upside to 2014 guidance · Strong gross margins and low share count provides huge profits for...
SeekingAlpha  Feb 17  Comment 
By Markus Aarnio: In this article, I will feature one healthcare stock that has seen intensive insider selling during the last 30 days. Intensive insider selling can be defined by the following three criteria: The stock was sold by three or...
Benzinga  Feb 13  Comment 
In a report published Thursday, MLV & Co analyst Graig C. Suvannavejh reiterated a Buy rating on Ligand Pharmaceuticals (NASDAQ: LGND), and raised the price target from $82.00 to $96.00. In the report, MLV & Co noted, “Yesterday, LGND...
SeekingAlpha  Feb 11  Comment 
Ligand Pharmaceuticals Incorporated (LGND) Q4 2013 Earnings Conference Call February 11, 2014 9:00 am ET Executives John Higgins - President and Chief Executive Officer John Sharp - Vice President, Finance and Chief Financial...
StreetInsider.com  Feb 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Ligand+Pharma+%28LGND%29+Tops+Q4+EPS+by+16c%3B+Issues+Light+Q1+Outlook/9150172.html for the full story.
DailyFinance  Feb 6  Comment 
LAVAL, QUEBEC -- (Marketwired) -- 02/06/14 -- ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today that its UK based subsidiary, ProMetic BioSciences Ltd. ("PBL"), has entered into a new agreement...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki